Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Clear Cell Renal Cell Carcinoma|Ovarian Cancer|Head and Neck Cancer|Colorectal Cancer|Non-small Cell Lung Cancer
Interventions: DRUG: BDC-3042|DRUG: Pembrolizumab
Sponsor: Bolt Biotherapeutics, Inc.